Tag:

Cadence Pharmaceuticals

Latest Headlines

Latest Headlines

Mallinckrodt expands pain portfolio with Cadence acquisition

Mallinckrodt has taken a major step toward hitting its goal of  boosting revenues as much as 11% a year  by announcing it would acquire Cadence Pharmaceuticals for $1.3 billion, or $14 a share, a 26% premium over Cadence's closing price yesterday.

Cadence wins FDA approval for pain, fever injection

The FDA has approved Cadence Pharmaceuticals' ($CADX) Ofirmev injection (acetaminophen) for the treatment of management of mild to moderate pain, the management of moderate to severe pain with

Pain startup lands $43M round, option to sell for up to $228M

In a flurry of deals, California startup Incline Therapeutics has landed a $43 million Series A to back the development of a pain med delivery system and landed a $3.5 million upfront for an option

Cadence shares surge in plans to resubmit pain therapy NDA

Shares of Cadence Pharmaceuticals (CADX) surged this morning after the developer said that it plans to resubmit its marketing application for the pain therapy Ofirmev within 30 days. Citing problems

Cadence to file with FDA using electronic gateway

Cadence Pharmaceuticals is ready to make regulatory submissions through the FDA's Electronic Submissions Gateway (ESG). The biopharma company worked with software provider ISI to implement its

FDA puts Cadence pain drug app on hold

The FDA has put Cadence Pharma's application to market its pain and fever therapy on hold. The agency alerted Cadence that it couldn't approve the drug--to be marketed as Ofirmev--until manufacturing

FDA extends Cadence drug review

Saying it needs more time to evaluate pharmacological data, the FDA has extended the review period for Cadence Pharmaceuticals' Acetavance until February 2010. The original PDUFA data was today.

Cadence's Acetavance gets priority review

The FDA has granted Cadence Pharmaceuticals priority review for its Acetavance NDA. Acetavance (intravenous acetaminophen) is being reviewed for the treatment of acute pain and fever in adults and

Cadence files NDA for Acetavance

Cadence Pharmaceuticals has submitted an NDA for Acetavance (intravenous acetaminophen), a potential treatment of acute pain and fever in adults and children. If approved, Acetavance would become the

Cadence Pharma pockets $86M in placement

In a new sign of a growing trend in biotechnology, Cadence Pharmaceuticals scored $86.6 million in a private placement of shares snapped up by a lengthy list of venture investors. In a deal